Contract facts
FederalVACCINES INCLUDING BUT NOT LIMITED TO: HEPATITIS A, HEPATITIS B, COMBINED HEPATITIS A AND B, MMR MEASLES, MUMPS, RUBELLA, TD TETANUS, DIPHTHERIA, TDAP TETANUS, DIPHTHERIA AND PERTUSSIS, MENINGITIS, RABIES, POLIO, TYPHOID INJECTABLE AND ORAL, YELLOW is a federal award for Division 1200 held by Sanofi Pasteur Inc. Estimated value —.
VACCINES INCLUDING BUT NOT LIMITED TO: HEPATITIS A, HEPATITIS B, COMBINED HEPATITIS A AND B, MMR MEASLES, MUMPS, RUBELLA, TD TETANUS, DIPHTHERIA, TDAP TETANUS, DIPHTHERIA AND PERTUSSIS, MENINGITIS, RABIES, POLIO, TYPHOID INJECTABLE AND ORAL, YELLOW
Incumbent footprint
Public recordSanofi Pasteur Inc — $3.7B obligated across 396 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15F06722A0000207?
15F06722A0000207 (Vaccines including BUT NOT limited to) is a Division 1200 award with an estimated value of —, currently held by Sanofi Pasteur Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15F06722A0000207?
Division 1200 awarded 15F06722A0000207 to Sanofi Pasteur Inc.
Who is the incumbent on 15F06722A0000207?
Sanofi Pasteur Inc is the incumbent with $3.7B across 396 related awards in SCOUT’s public footprint.
When does Sanofi Pasteur Inc’s 15F06722A0000207 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.